Article, Media, News
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Article, Media, News
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Media, News
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of…
Media, News
New tumour destruction data for Prescient’s OmniCAR and CellPryme platforms
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR and CellPryme cell therapy platforms at the prestigious International Society…
Media, News
Cell Therapies presentations from ISCT
Prescient was pleased to present data on our cell therapies at the prestigious International Society of Cell & Gene Therapy (ISCT) conference in Paris in…
Media, News
Major milestones Prescient Therapeutics (ASX:PTX) eyes in 2023
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for multiple types of cancers. The company’s platform consists of targeted…
RECENT POSTS
Categories
- Article (102)
- Media (6)
- News (295)
- Uncategorized (1)
- Webcast Video (7)